Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1771466

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1771466

Europe Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule, By Product, By Type, By Disease, By Age Group, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Europe Pharmaceutical Market Growth & Trends:

The Europe pharmaceutical market size is expected to reach USD 688.44 billion in 2030 and is projected to grow at a CAGR of 5.90% from 2025 to 2030, according to a new study conducted by Grand View Research, Inc. The market is driven by an increasing prevalence of diseases, a growing elderly population, and the approval and launch of novel products in the European region.

Overall, the pharmaceutical market in Europe is dominated by branded drugs; however, the generic drugs segment is anticipated to grow at the fastest rate over the forecast period. Loss of patent protection of key pharmaceutical products and increasing government initiatives to adopt generic drugs for the treatment are some of the key factors likely to boost generics demand in the coming years.

The capitalization opportunity is high for generic manufacturers in the European market as governments from each region are forming plans to meet the population's demand and lower healthcare-associated expenditure of the country. The expiration of patent exclusivities and the building need for cost-effective treatments are fueling the penetration of biosimilars and generics.

Novel molecule entry in this market typically takes 12-13 years and an investment of over USD 2.5 billion. In 2019, the total R&D expenditure on pharmaceutical R&D was USD 44,881.92 million. Increased competition from growing economies, such as China and Brazil, has accelerated the European economic investment in research to maintain its dominance in the market.

Improvements in healthcare infrastructure are promoting the adoption of novel pharmaceuticals. Furthermore, an increase in drug launches in Europe is projected to propel the market growth. For instance, in 2020, 62 drugs were approved in Europe and 97 medicines received marketing approval in European countries. The highest number of drug approvals were observed in the oncology segment.

Key pharmaceutical companies offer strong branded drugs in multiple therapeutic segments. Increasing R&D efforts, the growing adoption of novel therapies, and strategic collaborations are likely to boost the penetration of branded drugs. Strong pipeline products in different therapeutic areas are likely to fuel the growth of branded drugs in Europe.

Europe Pharmaceutical Market Report Highlights:

  • Conventional drugs (small molecules) dominated the market, with the largest share of 54.74% in 2024. These drugs are typically chemically synthesized and designed to target specific biological pathways, often by binding to receptors or enzymes.
  • The branded segment dominated the market with a revenue share of 66.49% in 2024, driving both innovation and exclusivity. These branded drugs benefit from regulatory frameworks that support their development, ensuring safety and efficacy.
  • The prescription segment held the largest share in the market, with a revenue of 86.76% in 2024, driven by rising demand for chronic disease treatments, an aging population, and regulatory support
  • The cancer segment dominated the market with a revenue share of 18.06% in 2024. The rising prevalence, driven by aging populations, lifestyle changes, and environmental factors, is fueling substantial market growth
  • The oral route of administration proved to be a significant contributor to revenue, with a share of 57.53% in 2024. The oral segment remains a cornerstone of drug delivery, encompassing tablets, capsules, and novel formulations like orally disintegrating tablets (ODTs).
Show more
Product Code: GVR-4-68038-357-7

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Europe Pharmaceutical Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
    • 3.3.3. Porter's Analysis
      • 3.3.3.1. Bargaining power of the suppliers
      • 3.3.3.2. Bargaining power of the buyers
      • 3.3.3.3. Threats of substitution
      • 3.3.3.4. Threats from new entrants
      • 3.3.3.5. Competitive rivalry
    • 3.3.4. PESTEL Analysis
      • 3.3.4.1. Political landscape
      • 3.3.4.2. Economic and Social landscape
      • 3.3.4.3. Technological landscape
      • 3.3.4.4. Environmental landscape
      • 3.3.4.5. Legal landscape

Chapter 4. Pharmaceutical Market: By Molecule Estimates & Trend Analysis

  • 4.1. Pharmaceutical Market: Molecule Segment Dashboard
  • 4.2. Pharmaceutical Market: By Molecule Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Biologics & Biosimilars (Large Molecules)
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Monoclonal Antibodies
      • 4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Vaccines
      • 4.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Cell & Gene Therapy
      • 4.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Conventional Drugs (Small Molecules)
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Europe Pharmaceutical Market: Product Estimates & Trend Analysis

  • 5.1. Europe Pharmaceutical Market: Product Segment Dashboard
  • 5.2. Europe Pharmaceutical Market: By Product Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Branded
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Generics
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Europe Pharmaceutical Market: Type Estimates & Trend Analysis

  • 6.1. Europe Pharmaceutical Market: Type Segment Dashboard
  • 6.2. Europe Pharmaceutical Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Prescription
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. OTC
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmaceutical Market: Disease Estimates & Trend Analysis

  • 7.1. Pharmaceutical Market: Disease Segment Dashboard
  • 7.2. Pharmaceutical Market: By Disease Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Cardiovascular diseases
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Cancer
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Diabetes
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Infectious diseases
    • 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Neurological disorders
    • 7.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Respiratory diseases
    • 7.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9. Autoimmune diseases
    • 7.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10. Mental health disorders
    • 7.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.11. Gastrointestinal disorders
    • 7.11.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.12. Women's Health Diseases
    • 7.12.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.13. Genetic and Rare genetic diseases
    • 7.13.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.14. Dermatological conditions
    • 7.14.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.15. Obesity
    • 7.15.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.16. Renal diseases
    • 7.16.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.17. Liver conditions
    • 7.17.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.18. Hematological disorders
    • 7.18.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.19. Eye conditions
    • 7.19.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.20. Infertility conditions
    • 7.20.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.21. Endocrine disorders
    • 7.21.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.22. Allergies
    • 7.22.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.23. Others
    • 7.23.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Pharmaceutical Market: Route of Administration Segment Dashboard
  • 8.2. Pharmaceutical Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 8.3. Oral
    • 8.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Tablets
    • 8.3.3. Capsules
    • 8.3.4. Suspensions
    • 8.3.5. Other
  • 8.4. Topical
    • 8.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Parenteral
    • 8.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Intravenous
    • 8.5.3. Intramuscular
  • 8.6. Inhalations
    • 8.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Other Routes of Administration
    • 8.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Pharmaceutical Market: Age Group Estimates & Trend Analysis

  • 9.1. Pharmaceutical Market: Age Group Segment Dashboard
  • 9.2. Pharmaceutical Market: By Age Group Movement Analysis, 2024 & 2030 (USD Million)
  • 9.3. Children & Adolescents
    • 9.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Adults
    • 9.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Geriatric
    • 9.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis

  • 10.1. Pharmaceutical Market: Distribution Channel Segment Dashboard
  • 10.2. Pharmaceutical Market: By Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 10.3. Hospital Pharmacy
    • 10.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4. Retail Pharmacy
    • 10.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5. Others
    • 10.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Europe Pharmaceutical Market: Regional Estimates & Trend Analysis

  • 11.1. Europe Pharmaceutical Market Share, By Region, 2024 & 2030 (USD Million)
    • 11.1.1. Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.1.2. UK
      • 11.1.2.1. Key Country Dynamics
      • 11.1.2.2. Target Disease Prevalence
      • 11.1.2.3. Regulatory Framework
      • 11.1.2.4. Reimbursement Framework
      • 11.1.2.5. UK Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.1.3. Germany
      • 11.1.3.1. Key Country Dynamics
      • 11.1.3.2. Target Disease Prevalence
      • 11.1.3.3. Regulatory Framework
      • 11.1.3.4. Reimbursement Framework
      • 11.1.3.5. Germany Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.1.4. France
      • 11.1.4.1. Key Country Dynamics
      • 11.1.4.2. Target Disease Prevalence
      • 11.1.4.3. Regulatory Framework
      • 11.1.4.4. Reimbursement Framework
      • 11.1.4.5. France Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.1.5. Italy
      • 11.1.5.1. Key Country Dynamics
      • 11.1.5.2. Target Disease Prevalence
      • 11.1.5.3. Regulatory Framework
      • 11.1.5.4. Reimbursement Framework
      • 11.1.5.5. Italy Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.1.6. Spain
      • 11.1.6.1. Key Country Dynamics
      • 11.1.6.2. Target Disease Prevalence
      • 11.1.6.3. Regulatory Framework
      • 11.1.6.4. Reimbursement Framework
      • 11.1.6.5. Spain Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.1.7. Denmark
      • 11.1.7.1. Key Country Dynamics
      • 11.1.7.2. Target Disease Prevalence
      • 11.1.7.3. Regulatory Framework
      • 11.1.7.4. Reimbursement Framework
      • 11.1.7.5. Denmark Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.1.8. Sweden
      • 11.1.8.1. Key Country Dynamics
      • 11.1.8.2. Target Disease Prevalence
      • 11.1.8.3. Regulatory Framework
      • 11.1.8.4. Reimbursement Framework
      • 11.1.8.5. Finland Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 11.1.9. Norway
      • 11.1.9.1. Key Country Dynamics
      • 11.1.9.2. Target Disease Prevalence
      • 11.1.9.3. Regulatory Framework
      • 11.1.9.4. Reimbursement Framework
      • 11.1.9.5. Norway Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.2. Rest of Europe
    • 11.2.1. Key Country Dynamics
    • 11.2.2. Target Disease Prevalence
    • 11.2.3. Regulatory Framework
    • 11.2.4. Reimbursement Framework
    • 11.2.5. Rest of Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

  • 12.1. Recent Developments & Impact Analysis by Key Market Participants
  • 12.2. Company Categorization
  • 12.3. Participant Overview
  • 12.4. Financial Performance
  • 12.5. Product Bench Marking
  • 12.6. Company Market Share Analysis, 2024
  • 12.7. Company Profiles
    • 12.7.1. F. Hoffmann-La Roche Ltd
      • 12.7.1.1. Participant's Overview
      • 12.7.1.2. Financial Performance
      • 12.7.1.3. Product Benchmarking
      • 12.7.1.4. Recent Developments/ Strategic Initiatives
    • 12.7.2. Bristol-Myers Squibb Company
      • 12.7.2.1. Participant's Overview
      • 12.7.2.2. Financial Performance
      • 12.7.2.3. Product Benchmarking
      • 12.7.2.4. Recent Developments/ Strategic Initiatives
    • 12.7.3. AstraZeneca
      • 12.7.3.1. Participant's Overview
      • 12.7.3.2. Financial Performance
      • 12.7.3.3. Product Benchmarking
      • 12.7.3.4. Recent Developments/ Strategic Initiatives
    • 12.7.4. Novartis AG
      • 12.7.4.1. Participant's Overview
      • 12.7.4.2. Financial Performance
      • 12.7.4.3. Product Benchmarking
      • 12.7.4.4. Recent Developments/ Strategic Initiatives
    • 12.7.5. Johnson & Johnson Services, Inc.
      • 12.7.5.1. Participant's Overview
      • 12.7.5.2. Financial Performance
      • 12.7.5.3. Product Benchmarking
      • 12.7.5.4. Recent Developments/ Strategic Initiatives
    • 12.7.6. Gilead Sciences
      • 12.7.6.1. Participant's Overview
      • 12.7.6.2. Financial Performance
      • 12.7.6.3. Product Benchmarking
      • 12.7.6.4. Recent Developments/ Strategic Initiatives
    • 12.7.7. GlaxoSmithKline plc.
      • 12.7.7.1. Participant's Overview
      • 12.7.7.2. Financial Performance
      • 12.7.7.3. Product Benchmarking
      • 12.7.7.4. Recent Developments/ Strategic Initiatives
    • 12.7.8. Merck & Co., Inc.
      • 12.7.8.1. Participant's Overview
      • 12.7.8.2. Financial Performance
      • 12.7.8.3. Product Benchmarking
      • 12.7.8.4. Recent Developments/ Strategic Initiatives
    • 12.7.9. Pfizer Inc.
      • 12.7.9.1. Participant's Overview
      • 12.7.9.2. Financial Performance
      • 12.7.9.3. Product Benchmarking
      • 12.7.9.4. Recent Developments/ Strategic Initiatives
    • 12.7.10. Sanofi
      • 12.7.10.1. Participant's Overview
      • 12.7.10.2. Financial Performance
      • 12.7.10.3. Product Benchmarking
      • 12.7.10.4. Recent Developments/ Strategic Initiatives
    • 12.7.11. GlaxoSmithKline plc.
      • 12.7.11.1. Participant's Overview
      • 12.7.11.2. Financial Performance
      • 12.7.11.3. Product Benchmarking
      • 12.7.11.4. Recent Developments/ Strategic Initiatives
    • 12.7.12. Boehringer Ingelheim GmbH
      • 12.7.12.1. Participant's Overview
      • 12.7.12.2. Financial Performance
      • 12.7.12.3. Product Benchmarking
      • 12.7.12.4. Recent Developments/ Strategic Initiatives

Chapter 13. Key Recommendations

Show more
Product Code: GVR-4-68038-357-7

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Europe Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
  • Table 4. Europe Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 5. Europe Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 6. Europe Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 7. Europe Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 8. Europe Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 9. Europe Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 10. Europe Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 11. Germany Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 12. Germany Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 13. Germany Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 14. Germany Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 15. Germany Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 16. Germany Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 17. Germany Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 18. UK Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 19. UK Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 20. UK Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 21. UK Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 22. UK Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 23. UK Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 24. UK Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 25. France Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 26. France Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 27. France Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 28. France Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 29. France Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 30. France Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 31. France Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 32. Italy Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 33. Italy Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 34. Italy Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 35. Italy Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 36. Italy Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 37. Italy Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 38. Italy Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 39. Spain Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 40. Spain Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 41. Spain Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 42. Spain Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 43. Spain Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 44. Spain Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 45. Spain Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 46. Denmark Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 47. Denmark Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 48. Denmark Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 49. Denmark Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 50. Denmark Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 51. Denmark Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 52. Denmark Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 53. Sweden Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 54. Sweden Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 55. Sweden Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 56. Sweden Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 57. Sweden Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 58. Sweden Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 59. Sweden Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 60. Norway Pharmaceutical Market, By Molecule, 2018 - 2030 (USD Billion)
  • Table 61. Norway Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 62. Norway Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 63. Norway Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
  • Table 64. Norway Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 65. Norway Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 66. Norway Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Europe Pharmaceutical Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Europe Pharmaceutical market: Molecule outlook and key takeaways
  • Fig. 15 Europe Pharmaceutical market: Molecule movement analysis & market share 2024 & 2030
  • Fig. 16 Biologics & biosimilars (large molecules) market, 2018 - 2030 (USD Billion)
  • Fig. 17 Monoclonal Antibodies market, 2018 - 2030 (USD Billion)
  • Fig. 18 Vaccines market, 2018 - 2030 (USD Billion)
  • Fig. 19 Cell & Gene Therapy market, 2018 - 2030 (USD Billion)
  • Fig. 20 Others market, 2018 - 2030 (USD Billion)
  • Fig. 21 Conventional drugs (small molecules) market, 2018 - 2030 (USD Billion)
  • Fig. 22 Europe Pharmaceutical market: Product outlook and key takeaways
  • Fig. 23 Europe Pharmaceutical market: Product movement analysis & market share 2024 & 2030
  • Fig. 24 Branded pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 25 Generics pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 26 Pharmaceutical market: Type outlook and key takeaways
  • Fig. 27 Pharmaceutical market: Type movement analysis & market share 2024 & 2030
  • Fig. 28 Prescription pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 29 OTC pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 30 Europe Pharmaceutical market: Disease outlook and key takeaways
  • Fig. 31 Europe Pharmaceutical market: Disease movement analysis & market share 2024 & 2030
  • Fig. 32 Cancer market, 2018 - 2030 (USD Billion)
  • Fig. 33 Cardiovascular diseases market, 2018 - 2030 (USD Billion)
  • Fig. 34 Diabetes market, 2018 - 2030 (USD Billion)
  • Fig. 35 Infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig. 36 Neurological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 37 Respiratory diseases market, 2018 - 2030 (USD Billion)
  • Fig. 38 Autoimmune diseases market, 2018 - 2030 (USD Billion)
  • Fig. 39 Mental health disorders market, 2018 - 2030 (USD Billion)
  • Fig. 40 Gastrointestinal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 41 Women's health diseases market, 2018 - 2030 (USD Billion)
  • Fig. 42 Genetic and rare genetic diseases market, 2018 - 2030 (USD Billion)
  • Fig. 43 Dermatological conditions market, 2018 - 2030 (USD Billion)
  • Fig. 44 Obesity market, 2018 - 2030 (USD Billion)
  • Fig. 45 Renal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 46 Liver conditions market, 2018 - 2030 (USD Billion)
  • Fig. 47 Hemotological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 48 Eye conditions market, 2018 - 2030 (USD Billion)
  • Fig. 49 Infertility conditions market, 2018 - 2030 (USD Billion)
  • Fig. 50 Endocrine disorders market, 2018 - 2030 (USD Billion)
  • Fig. 51 Allergies market, 2018 - 2030 (USD Billion)
  • Fig. 52 Other diseases market, 2018-2030 (USD Billion)
  • Fig. 53 Europe Pharmaceutical market: Route of administration outlook and key takeaways
  • Fig. 54 Europe Pharmaceutical market: Route of administration movement analysis & market share 2024 & 2030
  • Fig. 55 Oral pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 56 Tablets pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 57 Capsules pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 58 Suspensions pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 59 Others formulation pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 60 Topical pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 61 Parenteral pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 62 Intravenous market, 2018 - 2030 (USD Billion)
  • Fig. 63 Intramuscular market, 2018 - 2030 (USD Billion)
  • Fig. 64 Inhalations pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 65 Others pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 66 Pharmaceutical market: Age group outlook and key takeaways
  • Fig. 67 Pharmaceutical market: Age group movement analysis & market share 2024 & 2030
  • Fig. 68 Children & Adolescents pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 69 Adults pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 70 Geriatric pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 71 Europe Pharmaceutical market: Distribution Channel outlook and key takeaways
  • Fig. 72 Europe Pharmaceutical market: Distribution Channel movement analysis & market share 2024 & 2030
  • Fig. 73 Hospital Pharmacy pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 74 Retail Pharmacy pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 75 Others pharmaceutical market, 2018 - 2030 (USD Billion)
  • Fig. 76 Regional Outlook, 2024 & 2030
  • Fig. 77 Regional Market Dashboard
  • Fig. 78 Regional Market Place: Key Takeaways
  • Fig. 79 Europe
  • Fig. 80 Europe Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 81 UK Key Country Dynamics
  • Fig. 82 UK Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Germany Key Country Dynamics
  • Fig. 84 Germany Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 France Key Country Dynamics
  • Fig. 86 France Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Italy Key Country Dynamics
  • Fig. 88 Italy Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 Spain Key Country Dynamics
  • Fig. 90 Spain Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 91 Denmark Key Country Dynamics
  • Fig. 92 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 Sweden Key Country Dynamics
  • Fig. 94 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 95 Norway Key Country Dynamics
  • Fig. 96 Norway Market Estimates And Forecast, 2018 - 2030 (USD Billion)
  • Fig. 97 Rest of Europe Key Country Dynamics
  • Fig. 98 Rest of Europe Market Estimates And Forecast, 2018 - 2030 (USD Billion)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!